Petros Pharmaceuticals Releases Pro Forma Financial Statements Highlighting M&A Impact with Vivus Deconsolidation
I'm PortAI, I can summarize articles.
Petros Pharmaceuticals Inc. has released unaudited pro forma consolidated balance sheets reflecting the financial impact of its recent M&A activities, including the deconsolidation of subsidiaries and a settlement with Vivus. As of March 31, 2025, the company’s issued shares increased to 2,052,762, and additional paid-in capital rose to approximately $115.99 million. Adjustments also included a reduction in liabilities, particularly accounts payable and accrued expenses, providing a clearer view of the company's financial position post-transactions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments